India Speed-Up For Phase I Trial Approvals Draws Criticism
This article was originally published in PharmAsia News
Executive Summary
India's effort to step up its approval process for Phase I trials has drawn warnings from critics that the lack of expertise could be a problem. Currently, India allows only drug makers who have developed their drugs in the country to conduct early-stage trials. The government is trying to reduce its approval time for those trials, drawing criticism from some experts. The Indian drug industry is pressuring the government to reduce its approval time to 30 days, similar to the practice in Western countries. (Click here for more
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.